Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Published study affirms survival benefit of Efaproxyn in breast cancer-originating brain metastases
February 5th, 2006
Allos Therapeutics, Inc. (ALTH) announced the publication of results from its phase III REACH study of Efaproxyn (efaproxiral) in patients with brain metastases which suggest that the addition of Efaproxyn to whole brain radiation therapy (WBRT) may improve survival and response rates in patients with brain metastases, particularly those from breast cancer. Results of the study were reported in the January 1, 2006 edition of the Journal of Clinical Oncology (volume 24, issue 1). Authors of the manuscript analyzed data from the REACH study to assess the safety and efficacy of Efaproxyn when administered as an adjunct to WBRT in patients with...
Source: Women's Health Law Weekly (2006-02-05)
|
